CHRS Q1 2023 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$32M-46.0% YoY

Gross Profit

$16M48.0% margin

Operating Income

-$68M-208.9% margin

Net Income

-$76M-233.5% margin

EPS (Diluted)

$-0.94

QoQ Revenue Growth

-28.5%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$69M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$402M

Total Liabilities

$599M

Stockholders' Equity

-$197M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$60M	-46.0%
Gross Profit	$16M	$51M	-69.3%
Operating Income	-$68M	-$81M	+16.3%
Net Income	-$76M	-$96M	+21.2%

Revenue Segments

Product Revenue

$32M100%

Other

$83,0000%